Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
Status:
Recruiting
Trial end date:
2024-07-21
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, 2 arms study concerning patients with high-grade bone
sarcoma (HGBS) without complete remission after standard treatment at diagnosis or first
relapse.
In the first arm, patients will be treated with regorafenib + best supportive care (BSC) for
a maximum of 12 months as maintenance therapy after standard line therapy completion, whereas
in the second arm, patients will be treated with placebo + BSC (standard of care).
The comparison between this two arms will allow to determine whether or not regorafenib and
BSC is efficient for disease control, in terms of Progression-Free Survival improvement.